Retatrutide: The Triple Agonist Peptide Reshaping Obesity Research in 2026
Retatrutide is the world’s first triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. Discover what Australian researchers need to know about this groundbreaking metabolic peptide in 2026, including mechanism of action, published research highlights, and available formulations.